AU2023238504A1 — Crystal of fused tricyclic derivative or pharmaceutically acceptable salt thereof
Assigned to Chia Tai Tianqing Pharmaceutical Group Co Ltd · Expires 2024-10-31 · 2y expired
What this patent protects
Disclosed in the present application is a crystal of a fused tricyclic derivative or a pharmaceutically acceptable salt thereof; and specifically disclosed are a crystal of a compound of formula (I), a crystal of a pharmaceutically acceptable salt thereof, and a preparation metho…
USPTO Abstract
Disclosed in the present application is a crystal of a fused tricyclic derivative or a pharmaceutically acceptable salt thereof; and specifically disclosed are a crystal of a compound of formula (I), a crystal of a pharmaceutically acceptable salt thereof, and a preparation method therefor and the use thereof.
Drugs covered by this patent
- Akynzeo (NETUPITANT) · Helsinn Hlthcare
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.